5 completed. 4 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow LY3022855: new trials by email Literature Review of LY3022855 trials Research Report on LY3022855
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab - Pancreatic Cancer | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 11 | 2018-09-27 | 2025-01-09 |
| LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma LY3022855, Vemurafenib, Cobimetinib - Melanoma | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 5 | 2017-06-06 | 2024-07-17 |
| A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors LY3022855, Durvalumab, Tremelimumab - Solid Tumor | Phase 1 | Completed | Eli Lilly and Company | 72 | 2016-06-16 | 2023-10-16 |
| A Study of LY3022855 In Participants With Breast or Prostate Cancer LY3022855 - Neoplasms, Neoplasm Metastasis | Phase 1 | Completed | Eli Lilly and Company | 34 | 2015-05-01 | 2024-10-28 |
| A Study of IMC-CS4 in Subjects With Advanced Solid Tumors IMC-CS4 - Neoplasms | Phase 1 | Completed | Eli Lilly and Company | 52 | 2011-06-15 | 2024-09-19 |
Neoplasms (3) · Adenocarcinoma (1) · Melanoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Eli Lilly and Company (3) · Dana-Farber Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (5) · Belgium (1) · Czechia (1) · Israel (1)
Ana DeJesus, MD (1) · Elizabeth Buchbinder, MD (1)
PMID 32847933, PMID 33624233, PMID 33852104, PMID 41878443
2016 (1)